Lung Cancer Trials Ask AI to find trials
CompletedPhase 2NCT00125359
Official study title

Study of Tarceva and Targretin Oral Capsules in Patients With Advanced Lung Cancer

Study summary

The purpose of this study is to learn about the effects of two new anticancer drugs, erlotinib (Tarceva) and bexarotene (Targretin), when treating patients with advanced lung cancer. Erlotinib is approved by the Food and Drug Administration (FDA) for the treatment of non-small-cell lung cancer (NSCLC). Bexarotene is approved by the FDA for the treatment of cutaneous T-cell lymphoma. This combination of drugs is experimental.

Ask AI to explain this study
Start here

Key things to know

Main goalTreatment

This describes the study’s primary purpose.

What is being studiederlotinib and bexarotene

The study team can explain what participation involves.

Who it may be forNon-small cell lung cancer (NSCLC)

These are broad labels—not an eligibility decision.

Checked against the public recordLast updated Jan 8, 2019 · Source: ClinicalTrials.gov

Is enrollment open?Completed

Ask the study team to confirm whether enrollment is open.

What kind of study?Phase 2

Interventional

Where is it offered?2 U.S. locations

Locations may change over time.

Who runs it?Konstantin Dragnev

Study sponsor

01
Study overview

What this study is about

Purpose
Treatment
Study type
Interventional
Phase
Phase 2
Sponsor
Konstantin Dragnev
Interventions being studied
Drug: erlotinib and bexarotene
02
Explore related studies

How this study is categorized

These labels come from structured fields and exact terms in the public record.

Cancer type
Non-small cell lung cancer (NSCLC)→
03
Public criteria

Who may be able to participate

The sponsor separates these requirements into two groups. You do not need to interpret them alone—use them to guide a conversation with the study team.

Requirements people may need to meetInclusion criteria
  • Advanced NSCLC
  • Prior chemotherapy or radiotherapy is allowed.
Reasons someone may not be able to joinExclusion criteria

Hepatic or renal dysfunction

Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.

04
Study sites

U.S. locations

  • Norris Cotton Cancer CenterLebanon, New Hampshire
  • Mount Sinai School of MedicineNew York, New York

Source and freshness
Processed from ClinicalTrials.gov. Last public update: Jan 8, 2019. Always confirm current availability with the study team.

View original record ↗